NEW YORK (GenomeWeb) – Editas Medicine announced it has signed a three-year collaboration agreement with Cystic Fibrosis Foundation Therapeutics.

Under the terms of the agreement, CFFT will pay Editas up to $5 million to support discovery and development of CRISPR/Cas9-based therapies for cystic fibrosis. CFFT will also provide its network of experts to Editas. On its end, Editas has agreed to explore common mutations driving the disease as well as those not currently addressed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.